S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
CNSX:KBB

Kaneh Bosm Biotechnology Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume3.33 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kaneh Bosm Biotechnology Inc., formerly Anexco Resources Ltd., operates in the cannabis sector. The Company focuses on the deployment of kiosks to ultimate retail locations, and is evaluating various gold and lithium mining assets for potential acquisition. The Company is focused on identifying, acquiring and developing projects with a focus on precious metals deposits. The Company entered into a purchase agreement with Alps Innovations Group Inc. for North and South American rights to an intelligent automated retail kiosk, the BioCanna ADM Automated Cannabis retail system, for the dispensing of cannabis and related products in both medical and commercial markets (the Agreement). BioCanna ADM system is an automated dispensing machine, which is a hybrid between a bank automatic teller machine (ATM), and an intelligent retail kiosk. It operates its engineering, procurement and construction (EPC) division, a full-service engineering, procurement and construction service.

MarketRank

Overall MarketRank

0.68 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
WebN/A
Phone+1-604-2831722
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive KBB News and Ratings via Email

Sign-up to receive the latest news and ratings for KBB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kaneh Bosm Biotechnology (CNSX:KBB) Frequently Asked Questions

What stocks does MarketBeat like better than Kaneh Bosm Biotechnology?

Wall Street analysts have given Kaneh Bosm Biotechnology a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kaneh Bosm Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What other stocks do shareholders of Kaneh Bosm Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaneh Bosm Biotechnology investors own include Jubilee Metals Group PLC (JLP.L) (JLP), 156478 (DDD.L) (DDD), Clontarf Energy plc (CLON.L) (CLON) and ADVFN Plc (AFN.L) (AFN).

Who are Kaneh Bosm Biotechnology's key executives?

Kaneh Bosm Biotechnology's management team includes the following people:
  • Michael Martinz, President, Director
  • Rudy de Jonge, Chief Executive Officer, Director
  • Anthony Jackson, Chief Financial Officer (Age 34)
  • Kent Ausburn Ph.D., Chief Operating Officer, Director
  • Matthew Wyatt Lechtzier, Director (Age 53)

What is Kaneh Bosm Biotechnology's stock symbol?

Kaneh Bosm Biotechnology trades on the CNSX under the ticker symbol "KBB."

How do I buy shares of Kaneh Bosm Biotechnology?

Shares of KBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How can I contact Kaneh Bosm Biotechnology?

Kaneh Bosm Biotechnology's mailing address is 675 Hastings St W Suite 810, VANCOUVER, BC V6B 1N2, Canada. The company can be reached via phone at +1-604-2831722.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.